Stocks Health care LKFT

NASDAQ · Health care

Lakefront Biotherapeutics NV (LKFT)

Lakefront Biotherapeutics NV reported revenue of €1.1B in fiscal 2025, up 303.5% from a year earlier. Net income was €320.9M, a net margin of 28.9%. In fiscal 2025 capital spending exceeded operating cash flow by €271.2M. At December 31, 2025 it held €87.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 26, 2026.

Watch LKFT in 60 seconds

What Lakefront Biotherapeutics NV does

Lakefront Biotherapeutics NV is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LKFT.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Full financial statements: income, balance sheet and cash flow

Where LKFT ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Lakefront Biotherapeutics NV has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 23, 2026
   Foreign issuer update 6-K
2. September 15, 2026
   Foreign issuer update 6-K
3. September 8, 2026
   Foreign issuer update 6-K
4. September 8, 2026
   Foreign issuer update 6-K
5. September 1, 2026
   Foreign issuer update 6-K
6. August 25, 2026
   Foreign issuer update 6-K
7. August 25, 2026
   Foreign issuer update 6-K
8. August 25, 2026
   Foreign issuer update 6-K
9. August 18, 2026
   Foreign issuer update 6-K
10. August 12, 2026
    Foreign issuer update 6-K

Insider trades

What the people running Lakefront Biotherapeutics NV did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns LKFT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about LKFT

What does Lakefront Biotherapeutics NV do?

Lakefront Biotherapeutics NV is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LKFT.

Is Lakefront Biotherapeutics NV profitable?

Yes. In fiscal 2025 it reported net income of €320.9M on revenue of €1.1B, a net margin of 28.9%.

How much revenue does Lakefront Biotherapeutics NV make?

In fiscal 2025 Lakefront Biotherapeutics NV reported revenue of €1.1B. That is 303.5% more than a year earlier.

When did Lakefront Biotherapeutics NV last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 26, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 23, 2026.

Similar companies

Compare LKFT with

Compare LKFT with any company

Follow LKFT

Get an email when Lakefront Biotherapeutics NV files with the SEC: results, executive changes, material agreements and annual reports.

Follow LKFT: get an email when it files

Where the numbers come from

Financial figures are the values Lakefront Biotherapeutics NV tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.